Frankfurt - Delayed Quote EUR

RegenETP, Inc. (NJT.F)

0.2200 0.0000 (0.00%)
At close: June 15 at 10:03 AM GMT+2

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Richard Hague President, CEO & Director 448.46k -- 1960
Mr. Nikolai Sopko M.D., Ph.D. Chief Scientific Officer and VP of R&D -- -- --
Mr. Rich Haerle Vice President of Investor Relations & Strategy -- -- --
Mr. Mark E. Lehman J.D. Chief Legal Officer -- -- --
Angela Ziegler Vice President of Marketing & Public Relations -- -- --
Mr. Alain Adam Vice President of Sales -- -- --
Dr. Jon Anthony Joseph Burrows B.Sc., M.Sc., Ph.D. Senior VP of Corporate Development & President of Contract Services -- -- 1962
Mr. Ryan Mathis M.D. Chief Medical Officer -- -- --
Mr. Kolby Day Esq. Senior Vice President of Manufacturing Operations -- -- --

RegenETP, Inc.

1960 South 4250 West
Salt Lake City, UT 84104
United States
800 560 3983 https://www.polarityte.com
Full Time Employees: 
42

Description

RegenETP, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and other tissue regeneration products. The company was formerly known as PolarityTE, Inc. and changed its name to RegenETP, Inc. in August 2023. RegenETP, Inc. is headquartered in Salt Lake City, Utah.

Corporate Governance

RegenETP, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • Aug 18, 2023
    8-K: Corporate Changes & Voting Matters
    See Full Filing
  • Aug 15, 2023
    8-K: Corporate Changes & Voting Matters
    See Full Filing
  • Aug 01, 2023
    8-K: Corporate Changes & Voting Matters
    See Full Filing
  • Jul 10, 2023
    25-NSE: Notification filed by national security exchange to report the removal from listing and registration of matured
    See Full Filing
  • Jul 07, 2023
    8-K: Corporate Changes & Voting Matters
    See Full Filing

Upcoming Events

Apr 29, 2024 - May 04, 2024
RegenETP, Inc. Earnings Call